RXi Pharmaceuticals to Present on Retinoblastoma, Vitreoretinopathy at ARVO 2013

RXi Pharmaceuticals, biotechnology company headquartered in Westborough, Mass., has announced it will present its work on the use of its sd-rxRNAs in retinoblastoma and proliferative vitreoretinopathy therapies at the Association for Research in Vision and Ophthalmology 2013 Annual Meeting.

The presentations are titled “Development of sd-rxRNA for Retinoblastoma Therapy” and “Novel Anti-CTGF RNAi Therapy for Treatment of Proliferative Vitreoretinopathy (PVR) and Other Ocular Disorders.”

More Articles on Ophthalmology:
InSite Vision to Present at ARVO 2013
Glaucoma Management Lens to be Presented at ARVO 2013
Alcon Earns FDA Approval for Fixed-Dose Combination Glaucoma Therapy

Next Up in Ophthalmology